Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an ...

The CRISPR specialist said that a single 50mg infusion of NTLA-2002 – which switches off a gene involved in the potentially life-threatening inflammatory attacks that characterise HAE – resulted in an ...

This study, being conducted in South Africa, is similar to ImmunityBio’s U.S.-based trial QUILT 3.092, a phase 1 open-label study of CD19 t-haNK as a single agent and in combination with the company’s ...

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

The Insurance Regulatory and Development Authority of India (IRDAI) has released the IRDAI Assistant Manager Prelims Admit ...

Researchers assessed the safety and efficacy of suzetrigine, a non-opioid pain signal inhibitor, on moderate to severe acute pain from in patients with surgical and nonsurgical pain.

Wes Goodwin told the media in July it was time for his defense to return to “Dynasty Mode.” As the Tigers begin to ramp up to the season's final stretch, Barret ...

Crypto.com Arena, which celebrated its 25th anniversary this month, has completed phase three of its nine-figure, ...

The FDA has approved Botox® Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of platysma bands.

Caliway Biopharmaceuticals (Caliway) completed CBL-514 Phase 2b study for non-surgical fat reduction (CBL-0205, clinicaltrials.gov ID: NCT06005441) on October 22nd, 2024, with the topline results ...

Northwood Ravin submitted plans to Chapel Hill this summer to build a mix of housing options on a parcel north of its ...